Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.

Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.

Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.

Potential Risks of TTTS

If left untreated, TTTS can have devastating consequences. Medical research indicates that:

• 90% of the cases of untreated TTTS lead to loss of one or both twins.
• Despite treatment, only a 70% survival rate for both twins is assured.
• Severe forms can result in preterm labor, cardiac failure in the recipient twin, and organ failure in the donor twin.
• Complications in long-term survivors include neurological damage and developmental delay in surviving infants.

TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.

Why Identical Twin Pregnancies Are More Complicated

Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.

Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.

Other Twin Pregnancy Health Risks

Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:

1. Premature Birth

Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.

2. Gestational Hypertension and Preeclampsia

Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.

3. Anemia

Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.

4. Birth Defects

According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.

5. Amniotic Fluid Imbalances

When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.

6. Postpartum Hemorrhage

Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.

Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."

Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.

Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.

The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.

Just hours after GRAP-3 restrictions were implemented, authorities tightened pollution controls in Delhi and surrounding areas on Saturday evening by moving to GRAP-4.

Earlier in the afternoon, the Commission for Air Quality Management (CAQM)—the central agency responsible for monitoring and managing pollution in Delhi and neighbouring states—had imposed GRAP-3 curbs as the Air Quality Index (AQI) surpassed 400, entering the ‘Severe’ category.

By evening, the CAQM reported that the AQI, which was 431 at 4 pm, continued to rise and reached 441 by 6 pm. Under the GRAP system, air quality is divided into four levels: Poor (AQI 201–300), Very Poor (AQI 301–400), Severe (AQI 401–450), and Severe Plus (AQI above 450).

The CAQM stated, “Considering the current air quality trend and to prevent further deterioration in the region, the Sub-Committee on GRAP has decided to implement all measures under Stage IV of the existing GRAP – ‘Severe+’ Air Quality (Delhi AQI > 450) – with immediate effect across the entire NCR. These measures are in addition to the actions already in place under Stages I, II, and III.”

The commission added that the primary reason for the worsening AQI was the weak Western Disturbance moving toward north-west India, rather than local emissions.

GRAP 4 In Delhi: Schools Shift to Hybrid Classes

While schools in Delhi remain open, classes for several grades have moved to a hybrid format, combining both in-person and online learning. The Delhi Directorate of Education (DDE) issued a circular directing all government, aided, and private schools under DOE, NDMC, MCD, and Delhi Cantonment Board to adopt hybrid classes for students up to Class IX and XI wherever online teaching is feasible.

The circular, dated December 13, states: “All Heads of Schools…are directed to conduct classes in schools for children up to Class IX and XI in a ‘Hybrid Mode’ i.e., both physical and online mode (wherever online mode is feasible) with immediate effect until further orders.”

GRAP 4 In Delhi: Are Delhi Schools Open Today?

Yes, all schools under the Delhi Directorate of Education remain open. Students up to Class IX and Class XI can attend classes either physically or online, depending on what they or their parents choose. The hybrid arrangement will continue until further notice. The directive also applies to schools managed by NDMC, MCD, and Delhi Cantonment Board. School authorities have been asked to promptly inform parents and guardians about the arrangements.

GRAP 4 Activated as Pollution Worsens

The move comes after the Commission for Air Quality Management (CAQM) declared Stage 4 of GRAP with immediate effect, as Delhi’s Air Quality Index (AQI) surged into the ‘severe’ category. At 6 am on Sunday, the AQI in the city stood at 462, according to the Central Pollution Control Board’s Sameer app.

GRAP 4 In Delhi: Restrictions Under Stage 4

Stage 4 maintains all measures from Stage 3 and introduces stricter curbs to limit pollution. Among the new restrictions is a total ban on truck traffic entering Delhi, except for vehicles carrying essential goods or providing critical services. Trucks powered by LNG, CNG, electricity, and BS-VI diesel are exempt from the ban.

A widely sold nasal spray is being pulled from shelves across the United States after tests revealed mold and microbial contamination, prompting officials to urge consumers to stop using it right away.

MediNatura New Mexico issued a voluntary recall of ReBoost Nasal Spray on Wednesday, the US Food and Drug Administration said in a public notice. The action follows findings that one specific lot of the product contained yeast and mold, along with unsafe levels of microbial contamination.

Laboratory testing also identified the presence of Achromobacter, a type of bacteria that can cause infections, particularly in people with weakened immune systems. The FDA has advised customers to immediately discontinue use of the affected nasal spray.

Nasal Spray Recall: FDA Flags Microbial and Mold Contamination

MediNatura New Mexico Inc. has voluntarily recalled its ReBoost Nasal Spray after the product was found to contain yeast, mold, and microbial contamination. One of the organisms identified was the bacteria Achromobacter, detected at levels higher than safety limits, according to the US Food and Drug Administration.

The FDA warned that use of the spray could result in severe health effects, particularly for people with weakened immune systems. The agency noted a real risk of serious and potentially life-threatening infections in this group.

Nasal Spray Recall: Possible Symptoms to Watch For

The Hawaii State Department of Health, which also issued a recall notice, listed symptoms that may be linked to the contaminated spray. These include fever, sinus swelling, headaches, facial pain or pressure, and numbness in the face.

Consumers who notice any of these symptoms after using the product have been advised to contact a doctor or healthcare provider.

Nasal Spray Recall: No Adverse Events Reported So Far

As of December 10, MediNatura said it had not received any reports of health problems related to the recalled nasal spray. This information was confirmed by both the FDA and the Hawaii health department.

As per NBC, the nasal spray company was contacted for comment but did not receive a response by the time of publication.

Nasal Spray Recall: About the Product

ReBoost Nasal Spray is a homeopathic product that contains echinacea and other natural ingredients. The company markets it as a remedy for nasal congestion and related symptoms.

Nasal Spray Recall: Which Lots Are Affected

The recall applies to sprays packaged in a white and yellow box containing a 20 mL bottle. The affected lot number is 224268, with an expiration date of December 2027. The product carries NDC number 62795-4005-9 and UPC 787647101863.

What Consumers Should Do

The FDA has urged customers to stop using the nasal spray right away. Those who bought it directly from MediNatura can request a refund by emailing recall@medinatura.com. Consumers who purchased it through other retailers should return it to the place of purchase.

The product was sold both online and in physical stores across the United States.

Danish drugmaker Novo Nordisk has officially introduced its widely known diabetes medication Ozempic in India, pricing the starter dose of 0.25 mg at ₹2,200 per week. According to a Reuters report, the injectable medicine will be available in three strengths in the country: 0.25 mg, 0.5 mg and 1 mg.

Ozempic is a once-weekly injectable prescribed for people living with type 2 diabetes.

Ozempic Price In India

The weekly injection received approval from the US Food and Drug Administration in 2017 for treating type 2 diabetes. Since then, it has grown into a global blockbuster and is also commonly prescribed off-label for weight loss because of its appetite-suppressing effects.

The lowest strength will cost ₹2,200 per week. Prices for the higher doses have also been announced, as per the Reuters report.

Here are the details:

• 1 mg dose: ₹11,175/month
• 0.5 mg dose: ₹10,170/month
• 0.25 mg dose: ₹8,800/month

All you need To know About Ozempic

India’s drug regulator, the Central Drugs Standard Control Organisation (CDSCO), approved Ozempic, also known as semaglutide, in October this year for adults with type 2 diabetes.

As per the US FDA, Ozempic is prescribed along with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. It is also indicated to reduce the risk of major cardiovascular events in adults with type 2 diabetes who already have heart disease.

As per NDTV Profit, currently, Wegovy is priced at Rs 2,712 per week for the 0.25 mg dose, while the 0.5 mg dose costs Rs 3,462 weekly. The 1 mg dose is also priced at Rs 3,462 per week, and the 1.7 mg dose is available at Rs 4,100 per week. Mounjaro (tirzepatide), a combination therapy of GLP-1 receptor agonist and GIP that helps improve blood sugar control in adults with type 2 diabetes when paired with a healthy diet and regular exercise, is priced at Rs 13,500 per month for the 2.5 mg dose.

How Does Ozempic Help In Weight Loss?

Ozempic mimics the action of a naturally occurring hormone called GLP-1. Here’s how it supports weight loss, as outlined in an earlier HT report.

• It boosts insulin release when blood sugar levels increase.
• It slows down the emptying of food from the stomach, helping people feel full for longer after meals.
• At higher doses, it can also curb appetite, which may aid weight management efforts.

Possible Side-Effects Of Ozempic

As previously reported by Mayo Clinic, some potential side-effects of Ozempic include:

• An increased risk of inflammation of the pancreas.
• Possible gallbladder-related problems.
• According to the FDA, the most commonly reported side effects, seen in at least 5 per cent of patients taking Ozempic, include nausea, vomiting, diarrhoea, abdominal pain and constipation.

This article is intended for informational purposes only and should not be taken as a replacement for professional medical advice.